中炬高新：10月24日召开董事会会议

Group 1 - The core point of the article is that Zhongju Gaoxin (SH 600872) held its 11th fourth board meeting on October 24, 2025, to review the Q3 2025 report and other documents [1] - For the first half of 2025, Zhongju Gaoxin's revenue composition was 98.42% from manufacturing, 1.75% from real estate and services, and -0.17% from inter-segment elimination [1] - As of the report date, Zhongju Gaoxin's market capitalization was 14.3 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have sold overseas licenses worth 80 billion USD this year [1] - There is a discussion on the hot secondary market for biomedicine, while the primary market is experiencing a fundraising slowdown [1]